NEW YORK (
CHANGE IN RATINGS
upgraded at Sterne Agee to Buy from Neutral, Sterne Agee said. $15 price target. Compelling long term risk/reward.
Arch Coal downgraded to sell at TheStreet Ratings.
downgraded to hold at TheStreet Ratings.
downgraded at Janney from Neutral to Sell, Janney Montgomery said. $34 price target. Comps sales could turn negative in the next year.
upgraded at Piper from Neutral to Overweight, Piper Jaffray said. $22 price target. Industry is poised for a multi-year recovery cycle.
upgraded at Jefferies to Hold from Underperform, Jefferies said. $14.50 price target. Strong July quarter.
upgraded at Baird from Neutral to Outperform, Robert Baird said. $43 price target. Price momentum should continue in the second half of the year.
rated new Buy at Canaccord. $35 price target. Company is leveraged to new product releases at Apple.
upgraded at Piper from Neutral to Overweight, Piper Jaffray said. $93 price target. Drought fears have created an attractive entry point.
downgraded at Citigroup to Neutral from Buy, Citigroup said. $200 price target. Valuation call.
upgraded at Wells from Market Perform to Outperform, Wells Fargo said. Marriott deal should help create value.
Gaylord Entertainment upgraded at Wells Fargo to Outperform from Market Perform, Wells Fargo said. $43 to $48 price target. Pending transaction with Marriott and conversion to a REIT should provide value.
downgraded at JP Morgan from Overweight to Neutral, JP Morgan said. Valuation call, based on a $6 price target.
Helmerich & Payne
upgraded at Canaccord from Hold to Buy, Canaccord Genuity said. $64 price target. Company is relatively insulated from a softer rig market.
downgraded at Deutsche from Buy to Hold, Deutsche Bank said. $40 price target. Consensus earnings expectations appear too high.
downgraded at Goldman from Buy to Neutral, Goldman Sachs said. Valuation call, based on an $18 price target.
downgraded at Wedbush to Neutral, Wedbush said. $33 price target. Company has decided against a REIT conversion.
downgraded at Jefferies to Underperform from Hold, Jefferies said. $35 price target. Expect that solanezumab will fail its pivotal studies.
upgraded at FBR from Market Perform to Outperform, FBR Capital Markets said. $120 price target. DJ Basin is not fully factored into the current price.
downgraded at Wells from Market Perform to Underperform, Wells Fargo said. Company will be hurt by a flatter yield curve.
downgraded at Morgan Stanley from Overweight to Equal-weight, Morgan Stanley said. Macro risk should limit stock upside.
upgraded at Citigroup to Buy from Neutral, Citigroup said. $12.75 price target. Propylene price expected to increase.
downgraded at Nomura from Buy to Neutral, Nomura said. Valuation call, based on a $70 price target.
downgraded at Cantor to Hold. $59 price target. Company is facing another pipeline setback with Relistor.
Salix Pharmaceuticals downgraded at ThinkEquity from Buy to Hold, ThinkEquity said. $53 price target. Company lacks potential catalysts for the next year.
rated new Hold at Needham. Stock is already factoring in a NAND market rebound.
upgraded at JP Morgan to Overweight from Neutral, JP Morgan said. Pulp remains tail that wags the dog.
STOCK COMMENTS / EPS CHANGES
numbers raised at Credit Suisse.Shares of ACI now seen reaching $7, according to Credit Suisse. Estimates also increased, as the company is cutting costs. Neutral rating.
estimates, target cut at Credit Suisse.Shares of ALL now seen reaching $38, according to Credit Suisse. Estimates also reduced, given lower auto insurance results. Outperform rating.
added to Conviction Buy List at Nomura. AMZN was placed on the Conviction Buy list, according to Nomura. Company continues to deliver strong sales growth. $285 price target.
Abercrombie & Fitch
estimates lowered at Piper through 2014, Piper Jaffray said. Store checks show higher clearance activity. Equal-weight rating.
estimates, target lowered at Credit Suisse. Shares of ATR now seen reaching $52, according to Credit Suisse. Estimates also cut, given exposure to Europe and slower domestic growth. Neutral rating.
target raised at Oppenheimer to $73, Oppenheimer said. Business momentum remains strong. Outperform rating.
numbers boosted at Morgan Stanley.Shares of HFC now seen reaching $43, according to Morgan Stanley. Estimates also upped, given refinery expansion opportunities. Overweight rating.
Helmerich & Payne
numbers raised at UBS. Shares of HP now seen reaching $50, UBS said. Estimates also increased to reflect FQ3 beat. Neutral rating.
numbers lowered at Jefferies. Shares of LM now seen reaching $30, Jefferies said. Estimates also lowered on margin weakness. Buy rating.
Legg Mason numbers cut at Citigroup. Shares of LM now seen reaching $29.50, Citigroup said. Estimates also lowered to refect reduced EPS outlook. Buy rating.
estimates raised at UBS through 2014, UBS said. Marking to market higher phosphate, potash prices. Buy rating and $67 price target.
target raised at UBS to $50, UBS said. Recent pipeline successes and earnings upside. Buy rating.
numbers upped at BMO. NWL estimates were boosted through 2013, BMO Capital said. Company is seeing higher sales and expanding margins. Outperform rating and new $22 price target.
estimates, target increased at Keybanc through 2013. Company is cutting costs and has solid land holdings. Buy rating and new $15 price target.
numbers raised at Deutsche. Shares of S now seen reaching $4, according to Deutsche Bank. Estimates also increased, as the company is executing better. Hold rating.
estimates, target reduced at Credit Suisse. Shares now seen reaching $90, according to Credit Suisse. Estimates also cut, given lower paper volumes. Outperform rating.
>To submit a news tip, email:
READERS ALSO LIKE:
and become a fan on
This article was written by a staff member of TheStreet.